Linagliptin/Metformin Hcl

Brand name: Jentadueto

Rank #388 of 500 drugs by total cost

Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026

$24.3M

Total Cost

Share:

33,018

Total Claims

$24.3M

Total Cost

1,406

Prescribers

$737

Cost per Claim

1,914

Beneficiaries

47,150

30-Day Fills

$17K

Avg Cost/Provider

23

Avg Claims/Provider

Share of Medicare Part D Spending

0.01%

of total Medicare Part D spending

$24.3M of $275.65B

Top Prescribers by Cost

Top 10 prescribers of $24.3M total

🔎 Data Overview

👤

Average cost of $12,712 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Top Prescribers of Linagliptin/Metformin Hcl

#ProviderSpecialtyLocationClaimsCost
1Enrique GriegoFamily PracticeMcallen, TX185$255K
2Naomi Collazo GutierrezEndocrinologyManati, PR337$218K
3Matin SharafatkhahEndocrinologyBrooklyn, NY288$195K
4Rafael RodriguezInternal MedicineJackson Heights, NY112$181K
5Baltazar Rodriguez CruzGeneral PracticeLares, PR168$173K
6Alejandra SantiagoEndocrinologyPonce, PR282$171K
7Samayra Miranda RodriguezEndocrinologyDorado, PR238$170K
8Luis TorresGeneral PracticePonce, PR107$145K
9Yadiel Rivera-NievesInternal MedicineMayaguez, PR218$119K
10Jung BaeInternal MedicineLos Angeles, CA143$116K
11Sheila MercadoEndocrinologyManati, PR183$109K
12Lorenzo Ross RiveraGeneral PracticeGuayama, PR163$109K
13Manuel Alegre-HernandezEndocrinologySan Juan, PR109$108K
14Joo JangNurse PractitionerLeonia, NJ132$104K
15Razmik OhanjanianInternal MedicineGlendale, CA165$103K

Top prescribers ranked by total cost for this drug in 2023.

Related Drugs by Cost

#DrugTotal CostClaims
385Fremanezumab-Vfrm (Ajovy Autoinjector)$24.7M29,389
386Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro)$24.4M1,173,249
387Pegfilgrastim (Neulasta)$24.4M3,096
388Linagliptin/Metformin Hcl (Jentadueto)$24.3M33,018
389Ocrelizumab (Ocrevus)$24.2M639
390Fenofibrate (Fenofibrate)$24.2M670,936
391Empaglifloz/Linaglip/Metformin (Trijardy Xr)$23.9M28,001

Related Analysis

Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology